Heartland Bank & Trust Co Has $1.48 Million Holdings in Stryker Corporation $SYK

Heartland Bank & Trust Co raised its holdings in shares of Stryker Corporation (NYSE:SYK) by 98.2% during the 1st quarter, HoldingsChannel reports. The fund owned 4,489 shares of the medical technology company’s stock after purchasing an additional 2,224 shares during the period. Heartland Bank & Trust Co’s holdings in Stryker were worth $1,475,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Godfrey Financial Associates Inc. purchased a new stake in shares of Stryker in the fourth quarter worth approximately $26,000. Sankala Group LLC purchased a new position in Stryker during the fourth quarter valued at approximately $26,000. United Financial Planning Group LLC acquired a new position in Stryker in the 3rd quarter valued at approximately $27,000. Atlas Capital Advisors Inc. acquired a new position in Stryker in the 4th quarter valued at approximately $27,000. Finally, DJE Kapital AG purchased a new stake in Stryker in the 4th quarter worth approximately $28,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Price Performance

NYSE SYK opened at $319.78 on Friday. Stryker Corporation has a fifty-two week low of $281.00 and a fifty-two week high of $404.87. The stock’s 50-day moving average is $312.69 and its two-hundred day moving average is $336.82. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.11 and a quick ratio of 1.25. The firm has a market cap of $122.59 billion, a P/E ratio of 37.01, a price-to-earnings-growth ratio of 2.12 and a beta of 0.77.

Stryker (NYSE:SYK) last released its quarterly earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.98 by ($0.38). The company had revenue of $6.02 billion for the quarter, compared to the consensus estimate of $6.34 billion. Stryker had a return on equity of 23.42% and a net margin of 13.20%.The business’s revenue was up 2.6% compared to the same quarter last year. During the same quarter last year, the company posted $2.84 EPS. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. On average, analysts anticipate that Stryker Corporation will post 14.99 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be given a dividend of $0.88 per share. The ex-dividend date of this dividend is Tuesday, June 30th. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. Stryker’s dividend payout ratio is presently 40.74%.

Insider Buying and Selling at Stryker

In other news, VP M Kathryn Fink sold 5,220 shares of the business’s stock in a transaction on Monday, May 11th. The shares were sold at an average price of $283.85, for a total value of $1,481,697.00. Following the completion of the sale, the vice president directly owned 13,137 shares in the company, valued at approximately $3,728,937.45. The trade was a 28.44% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Ronda E. Stryker sold 310,000 shares of the company’s stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the sale, the director directly owned 1,924,880 shares of the company’s stock, valued at approximately $601,005,282.40. This represents a 13.87% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 323,264 shares of company stock worth $100,659,489 over the last 90 days. Insiders own 4.60% of the company’s stock.

Key Stories Impacting Stryker

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Stryker launched Mako RPS, a new handheld robotic power system for total knee replacement, expanding its Mako robotics portfolio beyond robotic-arm assisted surgery and potentially broadening adoption of robotic-assisted orthopedic procedures. Stryker expands Mako robotics portfolio with full market release of Mako RPS
• Positive Sentiment: Media coverage highlighted the full U.S. commercial launch of Mako RPS, reinforcing investor optimism that Stryker is strengthening its competitive position in orthopedic robotics. Stryker fully launches Mako robotic power system for knee surgery in US
• Positive Sentiment: Unusually heavy call-option buying suggested traders were positioning for more upside in SYK, which can sometimes add momentum to the shares.
• Positive Sentiment: RBC Capital reiterated its Buy rating on Stryker, providing another favorable signal from the analyst community. RBC Capital Sticks to Their Buy Rating for Stryker (SYK)
• Neutral Sentiment: MarketWatch noted that Stryker stock outperformed peers on a strong trading day, indicating relative strength but without a specific new company catalyst. Stryker Corp. stock outperforms competitors on strong trading day
• Neutral Sentiment: Analyst commentary on Stryker was mixed in broader healthcare-sector coverage, but no major negative surprise was indicated in the headlines provided. Analysts Offer Insights on Healthcare Companies: Shionogi & Co (OtherSGIOF) and Stryker (SYK)

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on SYK shares. Argus set a $370.00 target price on shares of Stryker in a research note on Thursday, July 9th. Needham & Company LLC cut their price objective on Stryker from $454.00 to $418.00 and set a “buy” rating for the company in a report on Friday, May 1st. Robert W. Baird set a $385.00 price objective on Stryker in a research report on Friday, May 1st. BTIG Research set a $371.00 target price on Stryker in a research note on Monday. Finally, JPMorgan Chase & Co. dropped their target price on Stryker from $445.00 to $400.00 and set an “overweight” rating on the stock in a research report on Friday, May 1st. One analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $392.52.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.